Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Coverage of drug costs: reference-based pricing

M McGregor1

  • 1Department of Medicine, Royal Victoria Hospital and McGill University, Montreal, Quebec.

The Canadian Journal of Cardiology
|June 17, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.

Neuroscience·2015
Same author

Smoking cessation in the workplace.

Occupational medicine (Oxford, England)·2013
Same author

The clinical effectiveness of negative pressure wound therapy: a systematic review.

Journal of wound care·2010
Same author

Basic research in acupuncture analgesia.

Canadian Medical Association journal·2010
Same author

Commentaries.

Canadian Medical Association journal·2010
Same author

A case of hereditary haemorrhagic telangiectasis.

Clinical proceedings·2010

British Columbia's reference-based pricing (RBP) for drug reimbursement is effective and equitable. This policy, despite criticism, demonstrates a reasonable approach to controlling healthcare expenses and warrants continued monitoring for comprehensive evidence.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Public Health

Background:

  • British Columbia has implemented reference-based pricing (RBP) since 1985 for drug reimbursement.
  • RBP reimburses drugs based on the cost of the lowest-priced equivalent-efficacy drug in a category.
  • This policy has faced criticism from the Canadian Cardiovascular Society.

Purpose of the Study:

  • To evaluate the validity of criticisms against British Columbia's reference-based pricing (RBP) policy.
  • To assess the evidence-based nature, cost-effectiveness, and equity of RBP.
  • To determine the suitability of continuing and monitoring the RBP policy.

Main Methods:

  • Analysis of claims regarding RBP's evidence base.
  • Evaluation of RBP's impact on healthcare costs.

Related Experiment Videos

  • Assessment of RBP's adherence to principles of equity and accessibility.

    • Main Results:

    • Criticisms that RBP is not evidence-based were found to be unfounded.
    • Claims of RBP's ineffectiveness in lowering healthcare costs were refuted.
    • Concerns regarding RBP contravening equity and accessibility principles were determined to be ill-founded.

    Conclusions:

    • British Columbia's reference-based pricing (RBP) policy is a sound strategy for drug cost containment.
    • The policy is deemed effective and equitable, contrary to recent criticisms.
    • Continued monitoring of RBP is recommended to gather robust evidence on its impact within the Canadian healthcare system.